CD4 and diabetic kidney disease: The inhibition of DNMT1 with 5-aza-2′-deoxycytidine (5-Aza) caused regulatory T cells to co-express CD4 and CD25 (CD4+CD25+), leading to significantly improved outcomes in mice with diabetic kidney disease.